Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- About
Catheter Precision Inc. (VTAK)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/08/2025: VTAK (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -77.18% | Avg. Invested days 14 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/08/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 3.05M USD | Price to earnings Ratio 0.06 | 1Y Target Price 2 |
Price to earnings Ratio 0.06 | 1Y Target Price 2 | ||
Volume (30-day avg) 1 | Beta -0.2 | 52 Weeks Range 1.49 - 15.77 | Updated Date 11/14/2025 |
52 Weeks Range 1.49 - 15.77 | Updated Date 11/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 33.63 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Revenue by Geography
Earnings Date
Report Date 2025-11-12 | When - | Estimate - | Actual -1.7046 |
Profitability
Profit Margin - | Operating Margin (TTM) -1338.68% |
Management Effectiveness
Return on Assets (TTM) -29.44% | Return on Equity (TTM) -184.52% |
Valuation
Trailing PE 0.06 | Forward PE - | Enterprise Value 5395732 | Price to Sales(TTM) 5.44 |
Enterprise Value 5395732 | Price to Sales(TTM) 5.44 | ||
Enterprise Value to Revenue 7.39 | Enterprise Value to EBITDA 0.27 | Shares Outstanding 1487266 | Shares Floating 1209287 |
Shares Outstanding 1487266 | Shares Floating 1209287 | ||
Percent Insiders 3.56 | Percent Institutions 5.43 |
Upturn AI SWOT
Catheter Precision Inc.
Company Overview
History and Background
Catheter Precision Inc. was founded in 2012. It is a medical device company focused on developing innovative catheter-based solutions. A significant milestone was the development of its steerable micro-catheter system, MoMau00ae.
Core Business Areas
- Medical Devices: Development and commercialization of advanced catheter-based medical devices, particularly for minimally invasive procedures. This includes their flagship MoMau00ae system.
Leadership and Structure
Information on the specific leadership team and organizational structure of Catheter Precision Inc. is not readily available in public domain resources. It is understood to be a publicly traded company with standard corporate governance.
Top Products and Market Share
Key Offerings
- MoMau00ae Micro-Catheter System: A highly steerable micro-catheter designed for complex minimally invasive procedures, enabling precise navigation in tortuous anatomy. Market share data, user numbers, and direct revenue figures for this specific product are not publicly disclosed. Key competitors in the steerable catheter market include companies like Abbott, Medtronic, and Boston Scientific.
Market Dynamics
Industry Overview
The medical device industry, particularly the segment for cardiovascular and interventional devices, is characterized by innovation, stringent regulatory requirements, and a growing demand for minimally invasive procedures driven by an aging population and advancements in technology.
Positioning
Catheter Precision Inc. aims to position itself as an innovator in the field of advanced catheter technology, focusing on niche applications and complex procedures where precise navigation is critical. Their competitive advantage lies in the proprietary design of their steerable micro-catheter.
Total Addressable Market (TAM)
The total addressable market for interventional cardiology and peripheral vascular devices is substantial and projected to grow significantly. Catheter Precision Inc. is positioned to address specific segments within this TAM, particularly those requiring advanced navigation capabilities.
Upturn SWOT Analysis
Strengths
- Innovative steerable catheter technology (MoMau00ae)
- Focus on niche, high-complexity procedures
- Potential for improved patient outcomes
Weaknesses
- Relatively new to market, limited brand recognition
- Reliance on a few core products
- Limited financial resources compared to larger competitors
- Challenges in scaling manufacturing and distribution
Opportunities
- Growing demand for minimally invasive procedures
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Technological advancements enabling new applications
Threats
- Intense competition from established medical device companies
- Regulatory hurdles and approval processes
- Reimbursement challenges
- Rapid technological obsolescence
- Economic downturns impacting healthcare spending
Competitors and Market Share
Key Competitors
- Abbott Laboratories (ABT)
- Medtronic plc (MDT)
- Boston Scientific Corporation (BSX)
Competitive Landscape
Catheter Precision Inc. faces a highly competitive landscape dominated by large, well-established medical device companies with extensive product portfolios, significant R&D budgets, and strong global distribution networks. Its advantage lies in its specialized, innovative technology targeting specific procedural needs, but it must overcome market entry barriers and compete on efficacy, safety, and cost-effectiveness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth for Catheter Precision Inc. has likely been focused on product development, clinical trials, and initial market introductions rather than significant revenue expansion, given its stage.
Future Projections: Future growth projections for Catheter Precision Inc. are speculative and depend heavily on successful commercialization of its technology, market adoption, and potential future funding rounds or partnerships. Analyst coverage may be limited.
Recent Initiatives: Recent initiatives likely involve efforts to gain regulatory approvals in key markets, establish distribution channels, and expand clinical use cases for their MoMau00ae system.
Summary
Catheter Precision Inc. is a medical device innovator with a promising steerable micro-catheter technology. While it holds potential for addressing complex procedures, it faces significant challenges in a competitive market dominated by larger players. Its growth hinges on successful commercialization, market adoption, and navigating regulatory and financial landscapes. Key focus should be on product differentiation and securing strategic partnerships.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company press releases
- Financial news outlets
- Industry analysis reports
- SEC filings (where available)
Disclaimers:
This analysis is based on publicly available information as of the current date. Financial data may be incomplete or subject to change. This is not investment advice, and investors should conduct their own due diligence.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Catheter Precision Inc.
Exchange NYSE MKT | Headquaters Fort Mill, SC, United States | ||
IPO Launch date 2018-09-27 | CEO, Chief Commercial Officer & Executive Chairman Mr. David A. Jenkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 22 | |
Full time employees 22 | |||
Catheter Precision, Inc. designs, manufactures, and sells medical technologies for the field of cardiac electrophysiology (EP) in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also offers LockeT, a suture retention device that temporarily secure sutures and aid clinicians in locating and removing sutures. The company is based in Fort Mill, South Carolina.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.